title: [Efficacy evaluation of an oral powder supplement enriched with eicosapentaenoic acid in cancer patients].
abstract: OBJECTIVE
  The beneficial effect of eicosapentaenoic acid in cancer patients is widely described especially in relation to its role in tumour cachexia. The aim of the study was to evaluate the efficacy of administration of a new oral powder supplement enriched with eicosapentaenoic acid compared to a standard liquid supplement in cancer patients.
  
  
  METHODS
  A total of 61 cancer patients, aged more than 18 years, were randomized to receive during a month a bonus of 600 kcal/ day to their regular diet with an oral powder supplement enriched with eicosapentaenoic acid (1.5 g) (RSI) or with a standard liquid supplement (RE). The following data were collected at baseline and after one month: the Patient-Generated Subjective Global Assessment (pg-SGA), anthropometric measurements (skin folds, circumferences and bioimpedance), dietary parameters (3-day food record), biochemical and inflammatory parameters (basic biochemistry, cytokines, prealbumin and Reactive C Protein). Quality of life was evaluated using the SF-36 questionnaire. At the end, scales were used to asses sensory perception, tolerance and satiety induced by the products and motivation to eat.
  
  
  RESULTS
  40 patients completed the study. After intervention, anthropometric parameters do not change and prealbumin values increased significantly in both groups (RSI 16.11 ± 5.66 mg/dl vs. 19.81 ± 6.75 mg/dl p < 0.05 and RE 6.13 ± 16.55 mg/dl vs. 19.03 ± 5.47 mg / dl p < 0.05). RSI group significantly decreased interferon gamma (INF-γ) values (0.99 ± 0.95 vs. 0.65 ± 0.92 pg/ml, p < 0.05). In contrast, RE group increased INF-γ after intervention (1.62 ± 1 27 vs. 2.2 ± 3.19 pg/ml, p < 0.05). There were no significant differences in hunger, appetite, satiety and intake capacity in both groups. The SF-36 scores improved in both groups.
  
  
  CONCLUSIONS
  Supplementation based on an oral powder formula enriched with 1.5 g EPA during one month in cancer patients improved certain inflammatory parameters. This product may be a novel and valuable option to be added to the nutritional intervention strategies used for cancer patients.
authors.affiliation: Unidad de Nutrición Clínica y Dietética, Hospital Universitario La Paz, IdiPAZ, Madrid, España. carmengomezcandela@telefonica.net
authors.forename: C
authors.initials: C
authors.lastname: Gómez-Candela
authors.forename: M
authors.initials: M
authors.lastname: Villarino Sanz
authors.forename: A
authors.initials: A
authors.lastname: Horrisberger
authors.forename: V
authors.initials: V
authors.lastname: Loria Kohen
authors.forename: L M
authors.initials: LM
authors.lastname: Bermejo
authors.forename: P
authors.initials: P
authors.lastname: Zamora Auñón
mesh_terms: D000328:Adult; D000368:Aged; D000886:Anthropometry; D002100:Cachexia / Q000188:drug therapy* / Q000209:etiology; D016207:Cytokines / Q000097:blood; D004032:Diet; D019587:Dietary Supplements; D015118:Eicosapentaenoic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007249:Inflammation / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009042:Motivation; D009369:Neoplasms / Q000150:complications / Q000628:therapy*; D018529:Nutritional Support; D011208:Powders; D011788:Quality of Life; D012528:Satiety Response; D012885:Skinfold Thickness; D011795:Surveys and Questionnaires; D055105:Waist Circumference; D055815:Young Adult
chemical_list: D016207:Cytokines; D011208:Powders; D015118:Eicosapentaenoic Acid